當(dāng)前位置：   首頁 > 需求大廳

本團(tuán)隊在進(jìn)行藥理研究中發(fā)現(xiàn)瑞戈非尼與帕唑帕尼存在治療肺纖維化的潛力，且動物實(shí)驗(yàn)藥效十分顯著，現(xiàn)二者針對肺纖維化適應(yīng)癥的專利申請已獲國家知識產(chǎn)權(quán)局受理。本團(tuán)隊向意向進(jìn)行瑞戈非尼、帕唑帕尼仿制生產(chǎn)的公司尋求合作，開發(fā)該藥物治療肺纖維化的新適應(yīng)癥，將技術(shù)轉(zhuǎn)化為產(chǎn)品，進(jìn)行新藥注冊并上市。 若有開發(fā)該藥物新適應(yīng)癥的意愿，可聯(lián)系我們。   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

1.丙氨酰谷氨酰胺及其注射液的研究開發(fā) 2.A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study). Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A. Vasa. 2015 Sep;44(5):371-9. doi: 10.1024/0301-1526/a000456. 3.2013 International Conference on Materials Engineering, ICMEN 2013 4.Orientation of substitution in the aromatic series. XVIII. Sulfonation of phenol by chlorosulfonic acid in solvents 5.Mechanism of reaction of chlorosulfonic acid with some aromatic compounds 6.Arzneimittelforschung. 1982;32(3):248-51. In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing. 7.Oral treatment with the Crataegus special extract WS 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension   [更多]

1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]

求DOF 2019年1-3期文獻(xiàn)   [更多]

求購氟吡草酮、砜吡草唑原藥各70kg，含量80%以上   [更多]

標(biāo)題：求購克拉霉素緩釋片USP41標(biāo)準(zhǔn) 詳細(xì)要求： 需求名稱：克拉霉素緩釋片標(biāo)準(zhǔn) 具體要求：USP42 要求時間：請在2019年05月15日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

藥復(fù)核標(biāo)準(zhǔn)匯編(2003)中關(guān)于復(fù)方α-酮酸片的標(biāo)準(zhǔn)   [更多]

① 從任務(wù)主手中獲取指定企業(yè)的年報文件， ② 將年報中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報中沒有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫， ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 價格215元完成已有的86份年報數(shù)據(jù)提取(≈2.5元/份)（填寫完了審核通過，每個年報要求把所有產(chǎn)品銷售額收集填寫完）， ⑤ 如若審核發(fā)現(xiàn)有填錯，填漏；以每填錯，填漏一個數(shù)據(jù)1元計量扣除賞金。   [更多]

1、規(guī)模較小，生產(chǎn)許可證、GMP有效期內(nèi)，可正常生產(chǎn) 2、固體制劑（片劑、膠囊） 3、地區(qū)：華東六省、海南均可 4、中介勿擾   [更多]